DBV Technologies Q3 net loss widens 94% to $64.5 million
DBVT•DBV Technologies’ third-quarter 2026 net loss widened 94% year over year to $64.5 million. Cash and cash equivalents totaled $165.7 million at September 30, funding operations into the third quarter of 2027; the company submitted its VIASKIN Peanut Patch application for children aged 4–7 to the FDA and requested Priority Review.
1. Quarterly results and filing
DBV Technologies’ third-quarter 2026 net loss widened 94% year over year to $64.5 million, while operating expenses climbed 79% to $66.3 million. The company had $165.7 million in cash and cash equivalents at September 30, which it said would fund operations into the third quarter of 2027. It submitted the VIASKIN Peanut Patch application for children aged 4–7 to the FDA and requested Priority Review.
